Literature DB >> 25234945

Arginase 2 deficiency results in spontaneous steatohepatitis: a novel link between innate immune activation and hepatic de novo lipogenesis.

Laura A Navarro1, Alexander Wree2, Davide Povero2, Michael P Berk3, Akiko Eguchi2, Sudakshina Ghosh4, Bettina G Papouchado5, Serpil C Erzurum4, Ariel E Feldstein6.   

Abstract

BACKGROUND & AIMS: Innate immune activation has been postulated as a central mechanism for disease progression from hepatic steatosis to steatohepatitis in obesity-related fatty liver disease. Arginase 2 competes with inducible nitric oxide synthase (iNOS) for its substrate and the balance between these two enzymes plays a crucial role in regulating immune responses and macrophage activation. Our aim was to test the hypothesis that arginase 2 deficiency in mice favours progression from isolated hepatic steatosis, induced by high fat feeding, to steatohepatitis.
METHODS: Arginase 2-knockout (Arg2(-/-)) mice were studied for changes in liver histology and metabolic phenotype at baseline and after a short term course (7 week) feeding with a high fat (HFAT) diet. In additional experiments, Arg2(-/-) mice received tail vein injections of liposome-encapsulated clodronate (CLOD) over a three-week period to selectively deplete liver macrophages.
RESULTS: Unexpectedly, Arg2(-/-) mice showed profound changes in their livers at baseline, characterized by significant steatosis as demonstrated with histological and biochemical analysis. These changes were independent of systemic metabolic parameters and associated with marked mRNA level increases of genes involved in hepatic de novo lipogenesis. Liver injury and inflammation were present with elevated serum ALT, marked infiltration of F4/80 positive cells, and increased mRNA levels of inflammatory genes. HFAT feeding exacerbated these changes. Macrophage depletion after CLOD injection significantly attenuated lipid deposition and normalized lipogenic mRNA profile of livers from Arg2(-/-) mice.
CONCLUSIONS: This study identifies arginase 2 as a novel link between innate immune responses, hepatic lipid deposition, and liver injury.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Arginase 2; Inflammation; Innate immunity; Liver fibrosis; Macrophage activation; Non-alcoholic fatty liver disease; Steatohepatitis

Mesh:

Substances:

Year:  2014        PMID: 25234945      PMCID: PMC4736721          DOI: 10.1016/j.jhep.2014.09.015

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  40 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine.

Authors:  N van Rooijen; A Sanders; T K van den Berg
Journal:  J Immunol Methods       Date:  1996-06-14       Impact factor: 2.303

Review 3.  Comparative properties of arginases.

Authors:  C P Jenkinson; W W Grody; S D Cederbaum
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  1996-05       Impact factor: 2.231

4.  Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene.

Authors:  O Shi; S M Morris; H Zoghbi; C W Porter; W E O'Brien
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

5.  Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage-like cell line.

Authors:  T Gotoh; T Sonoki; A Nagasaki; K Terada; M Takiguchi; M Mori
Journal:  FEBS Lett       Date:  1996-10-21       Impact factor: 4.124

6.  Exacerbation of alcoholic liver injury by enteral endotoxin in rats.

Authors:  P Mathurin; Q G Deng; A Keshavarzian; S Choudhary; E W Holmes; H Tsukamoto
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

7.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

Authors:  C A Matteoni; Z M Younossi; T Gramlich; N Boparai; Y C Liu; A J McCullough
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

8.  Distinct arginase isoforms expressed in primary and transformed macrophages: regulation by oxygen tension.

Authors:  C A Louis; J S Reichner; W L Henry; B Mastrofrancesco; T Gotoh; M Mori; J E Albina
Journal:  Am J Physiol       Date:  1998-03

9.  Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis.

Authors:  S Q Yang; H Z Lin; M D Lane; M Clemens; A M Diehl
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

Review 10.  Inducible nitric oxide synthase in the liver: regulation and function.

Authors:  B S Taylor; L H Alarcon; T R Billiar
Journal:  Biochemistry (Mosc)       Date:  1998-07       Impact factor: 2.487

View more
  25 in total

Review 1.  Liver macrophages in tissue homeostasis and disease.

Authors:  Oliver Krenkel; Frank Tacke
Journal:  Nat Rev Immunol       Date:  2017-03-20       Impact factor: 53.106

2.  Association between circulating inflammatory molecules and alcoholic liver disease in men.

Authors:  Bao-Ge Qu; Weimin Bi; Yi-Guo Jia; Yuan-Xun Liu; Hui Wang; Ji-Liang Su; Li-Li Liu; Zhong-Dong Wang; Ya-Fei Wang; Xing-Hai Han; Jin-Dun Pan; Guang-Ying Ren; Wen-Juan Hu
Journal:  Cell Stress Chaperones       Date:  2016-06-21       Impact factor: 3.667

Review 3.  Dietary and metabolic modulators of hepatic immunity.

Authors:  Antonella Carambia; Johannes Herkel
Journal:  Semin Immunopathol       Date:  2017-11-06       Impact factor: 9.623

4.  Simultaneous Inhibition of Peripheral CB1R and iNOS Mitigates Obesity-Related Dyslipidemia Through Distinct Mechanisms.

Authors:  Célia Roger; Chloé Buch; Tania Muller; Julia Leemput; Laurent Demizieux; Patricia Passilly-Degrace; Resat Cinar; Malliga R Iyer; George Kunos; Bruno Vergès; Pascal Degrace; Tony Jourdan
Journal:  Diabetes       Date:  2020-07-17       Impact factor: 9.461

5.  Myeloid-specific deletion of Zfp36 protects against insulin resistance and fatty liver in diet-induced obese mice.

Authors:  Valentina Caracciolo; Jeanette Young; Donna Gonzales; Yingchun Ni; Stephen J Flowers; Ross Summer; Scott A Waldman; Jason K Kim; Dae Young Jung; Hye Lim Noh; Taekyoon Kim; Perry J Blackshear; Danielle O'Connell; Robert C Bauer; Caleb B Kallen
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-03-06       Impact factor: 4.310

Review 6.  Nitric oxide in liver diseases.

Authors:  Yasuko Iwakiri; Moon Young Kim
Journal:  Trends Pharmacol Sci       Date:  2015-05-28       Impact factor: 14.819

7.  Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.

Authors:  Resat Cinar; Malliga R Iyer; Ziyi Liu; Zongxian Cao; Tony Jourdan; Katalin Erdelyi; Grzegorz Godlewski; Gergő Szanda; Jie Liu; Joshua K Park; Bani Mukhopadhyay; Avi Z Rosenberg; Jeih-San Liow; Robin G Lorenz; Pal Pacher; Robert B Innis; George Kunos
Journal:  JCI Insight       Date:  2016-07-21

Review 8.  Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment.

Authors:  Meric Erikci Ertunc; Gökhan S Hotamisligil
Journal:  J Lipid Res       Date:  2016-06-21       Impact factor: 5.922

Review 9.  Danger signals in liver injury and restoration of homeostasis.

Authors:  Hui Han; Romain Desert; Sukanta Das; Zhuolun Song; Dipti Athavale; Xiaodong Ge; Natalia Nieto
Journal:  J Hepatol       Date:  2020-05-01       Impact factor: 25.083

10.  Increased mitochondrial arginine metabolism supports bioenergetics in asthma.

Authors:  Weiling Xu; Sudakshina Ghosh; Suzy A A Comhair; Kewal Asosingh; Allison J Janocha; Deloris A Mavrakis; Carole D Bennett; Lourdes L Gruca; Brian B Graham; Kimberly A Queisser; Christina C Kao; Samuel H Wedes; John M Petrich; Rubin M Tuder; Satish C Kalhan; Serpil C Erzurum
Journal:  J Clin Invest       Date:  2016-05-23       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.